These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 28231855)

  • 21. High-risk histopathologic features in local advanced conjunctival melanoma.
    Zhu T; Zong C; Li Y; Jia S; Shi H; Tian H; Rao Y; Zhang X; Ge S; Fan X; Li Y; Jia R; Xu S
    Acta Ophthalmol; 2024 Aug; 102(5):e851-e861. PubMed ID: 38420891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple predictive biomarker testing in melanoma: Another challenge in identifying the optimal approach on cytological samples.
    Iaccarino A; Nacchio M; Acanfora G; Pisapia P; Malapelle U; Bellevicine C; Troncone G; Vigliar E
    Cytopathology; 2023 May; 34(3):198-203. PubMed ID: 36658094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells.
    Sciarretta F; Fulci C; Palumbo C; Rotili D; Tentori L; Graziani G; Caccuri AM
    Chemotherapy; 2019; 64(3):138-145. PubMed ID: 31639786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and NRAS mutated melanoma: Different Ca
    Esteves GNN; Ferraz LS; Alvarez MMP; Costa CAD; Lopes RM; Tersariol ILDS; Rodrigues T
    Cell Calcium; 2020 Sep; 90():102241. PubMed ID: 32562975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
    Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
    Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
    Atefi M; Avramis E; Lassen A; Wong DJ; Robert L; Foulad D; Cerniglia M; Titz B; Chodon T; Graeber TG; Comin-Anduix B; Ribas A
    Clin Cancer Res; 2014 Jul; 20(13):3446-57. PubMed ID: 24812408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
    Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
    J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
    Massi D; Brusa D; Merelli B; Ciano M; Audrito V; Serra S; Buonincontri R; Baroni G; Nassini R; Minocci D; Cattaneo L; Tamborini E; Carobbio A; Rulli E; Deaglio S; Mandalà M
    Ann Oncol; 2014 Dec; 25(12):2433-2442. PubMed ID: 25223485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
    Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
    Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.
    Lassalle S; Nahon-Esteve S; Frouin E; Boulagnon-Rombi C; Josselin N; Cassoux N; Barnhill R; Scheller B; Baillif S; Hofman P
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.
    Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D
    Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma brain metastases harboring BRAF
    Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
    J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
    Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
    J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.